Rethinking Blood Clot Risks: Route Alone May Not Define Menopausal Hormone Therapy Safety
New research is reshaping our understanding of blood clot risks associated with menopausal hormone therapy (MHT), suggesting that simply choosing a transdermal (skin patch, gel, or spray) over an oral route might not guarantee safety for all women. While a major Danish study recently published in The BMJ confirmed higher venous thromboembolism (VTE) risk with oral MHT, particularly high doses over a year, it also flagged that specific transdermal regimens could still pose risks, such as a doubled risk of myocardial infarction with transdermal combined cyclic therapy. This nuanced view challenges the long-held belief that transdermal options are uniformly safer, pushing for a more personalized approach to treatment.







